Importance

Loading Importance Indicators...

Abstract

Adenosine A.sub.2 agonists of the formula ##STR1## wherein R is hydrogen, alkyl, cycloalkyl or phenylalkyl; R.sub.1 is selected from the group consisting of a) optionally substituted phenyl or naphthyl; b) --(CH.sub.2).sub.m --Het wherein m is 0-3 and Het is a 5 or 6 membered heterocyclic aromatic or non-aromatic ring, optionally benzocondensed; c) cycloalkyl optionally containing unsaturations or alkenyl; and ##STR2## wherein n is 0-4; R.sub.2 is hydrogen, methyl or phenyl; R.sub.5 is hydrogen, alkyl, cycloalkyl, cycloalkenyl or phenylalkyl; or R.sub.2 and R.sub.5 form a 5 or 6-membered carbocyclic ring; or R.sub.5 is hydrogen and R.sub.2 and R.sub.4 form an oxo group or a corresponding acetalic derivative; R.sub.4 is OH, NH.sub.2, dialkylamino, halogen or cyano; and R.sub.3 is alkyl, cycloalkyl, phenyl or benzyl; provided that when R is different from hydrogen or when R is hydrogen and R.sub.3 is phenyl or benzyl, R.sub.1 can also be alkyl, useful in the treatment of cardiovascular pathologies and nervous system diseases, a process for the preparation thereof and pharmaceutical compositions containing them are disclosed.

Loading the Abstract Image...

First Claim